Northwest Biotherapeutics Inc (NWBO OTCQB) stock market data APIs
$0.2189
0.02(9.1%)
as of July 10, 2025
Try our APIs with
free plan!
Northwest Biotherapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Northwest Biotherapeutics, Inc., a biotechnology company, focuses on developing personalized immune therapies for cancer. The company develops DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product candidate is the DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, that has completed Phase I clinical trials to treat inoperable solid tumors, as well as a range of types of cancers. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.
Prev. Close
0.2189
Open
0.2407
High
0.2407
Low
0.2189
52 wk Range
0.17-0.48
Market Cap
321 M
Shares Outstanding
1 458 M
Revenue
1 473 K
EPS
-0.0144
Beta
-1.092
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Northwest Biotherapeutics Inc data using free add-ons & libraries
Get Northwest Biotherapeutics Inc Fundamental Data
Northwest Biotherapeutics Inc Fundamental data includes:
- Net Revenue: 1 473 K
- EBITDA: -66 325 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-08
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Northwest Biotherapeutics Inc News
New
Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma
Culmination Of Over 20 Years Of Research And Clinical Development BETHESDA, Md., Dec. 21, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing D...
Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application
BETHESDA, Md., Nov. 22, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, provi...
Northwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization Application
BETHESDA, Md., Oct. 13, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, provi...
Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board
BETHESDA, Md., Sept. 12, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, anno...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
